On October 14, 2022 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, reported a poster presentation at the SITC (Free SITC Whitepaper) 2022 Annual Meeting being held November 8-12, 2022 (Press release, Corbus Pharmaceuticals, OCT 14, 2022, View Source [SID1234622035]). The poster will share the updated preclinical validation of the drug candidate CRB-601.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Details:

Title: CRB-601, a selective integrin avβ8 blocking antibody, exhibits potent anti-tumor activity in anti-PD-1 resistant models

Authors: Daqing Wang, Vaishali Shinde, Maneesh Singh, Rachael Brake, and Andrew Kolodziej

Abstract Number: 815

Date / Time: November 10 – November 11, 9:00 am – 9:00 pm ET

CRB-601 is a potent and selective integrin αvβ8 blocking monoclonal antibody that can overcome tumor immune exclusion and enhance the activity of immune checkpoint inhibitors in vivo. Investigational New Drug (IND) enabling studies are currently underway with a plan to explore the anti-tumor activity of this agent clinically in 2023.

The CRB-601 abstract will be available on the SITC (Free SITC Whitepaper) website as of November 7th and the poster will be made available on the Company website on November 10th.